Head-to-head evidence
Ainuovirine vs Etravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Ainuovirine
Marketed by Kainos Medicine and partners
NCT01348516 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: June 2028 · NCT07631897 (registry estimate)
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ainuovirine's landscape · Etravirine's landscape